GlaxoSmithKline PLC ADR (GSK NYSE) stock market data APIs
$48.6403
-0.08(-0.2%)
as of December 8, 2025
Try our APIs with
free plan!
GlaxoSmithKline PLC ADR Financial Data Overview
Price chart is built with
Anychart
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom.
Prev. Close
48.6403
Open
48.5608
High
48.6819
Low
48.4838
52 wk Range
30.4134-49.31
Market Cap
97 840 M
P/E Ratio
13.6921
Shares Outstanding
2 019 M
Revenue
32 166 M
EPS
1.4562
Dividends (Yield)
0.0349
Beta
0.23
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with GlaxoSmithKline PLC ADR (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GlaxoSmithKline PLC ADR data using free add-ons & libraries
Get GlaxoSmithKline PLC ADR Fundamental Data
GlaxoSmithKline PLC ADR Fundamental data includes:
- Net Revenue: 32 166 M
- EBITDA: 9 519 M
- Earnings Per Share: 3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-29
- EPS/Forecast: 1.17
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GlaxoSmithKline PLC ADR News
New
Trump signs memo to align U.S. vaccines for children with practices from other countries
[A parent holds a syringe ready for vaccination, focusing on the inoculation process. A child sits nearby, demonstrating a common healthcare practice and the importance of immunization] President Don...
Catalyst Watch: Spotlight on the Fed, Costco earnings, and Nasdaq 100 additions
[Amazing golden hour in modern New York. Sunset time footage from drone. Setting sun dazzles the scenery.] Vadym Terelyuk/iStock via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdo...
Is GSK (LSE:GSK) Fairly Priced After Its Recent Share Price Rally? A Fresh Look at Valuation
GSK (LSE:GSK) has quietly kept shareholders happy this year, with the stock climbing about 34% year to date and roughly 42% over the past year, backed by steady revenue and earnings growth. See our l...
CDC vaccine panel voting on hepatitis b shots postponed over confusion
[Advisory Committee On Immunization Practices Holds Meeting At CDC Headquarters] Elijah Nouvelage/Getty Images News An influential vaccine advisory panel to the CDC delayed voting on questions regard...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
